# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹3,264.4 Cr** Q1 FY26 (+0.6%) * **Gross Margin:** **68% to 69%** Q1 FY26 * **Net Debt:** **~₹1,500 Cr** Q1-end * **Gross Debt:** **~₹3,200 Cr** Q1-end * **Capex:** **~₹180 Cr** Q1 FY26 (65% tangible / 35% intangible) ## B. Margins & Profitability * **Portfolio Optimization:** Gross margin profile is strengthening following the strategic discontinuation of low-value tail-end brands. * **Sustainable Earnings Quality:** Management confirmed that operating income from royalties and incentives are recurring core activities, supporting the high-60s margin floor. * **Geographic Mix:** Future profitability gains are tied to a focus on branded markets across India, Europe, and emerging economies. * **Tax Headwinds:** While P&L impacts are being finalized, **one-time taxes** related to the AbbVie payment will be recognized in **Q2**. ## C. Debt & Liquidity * **Deleveraging Milestone:** Following the AbbVie payment receipt, the company expects to transition to a **consolidated net cash positive** position. * **Working Capital Pressure:** Recent gross debt expansion was driven by inventory buildup for European launches and higher debtor levels. * **Non-Recurring Outflows:** Cash flow was impacted by one-off severance payments for **LCDF** and costs associated with plant closures. ## D. Capital Allocation * **Investment Discipline:** Capex remains aligned with full-year guidance, maintaining a consistent split between tangible and intangible asset investments. --- # 2. Product & Therapy Performance ## A. Key Figures * **India Formulation Sales:** **₹1,239.9 Cr** (+3.7% YoY) * **India Consumer Care (GCC) Growth:** **20%** Primary Sales Growth * **North America Revenue:** **₹778 Cr** / **$9.1 Cr** (+8.9% QoQ) * **Market Share (India):** **2.3%** Overall (Rank 13) · **60%+** Candid Powder * **B. S. Portfolio:** **208** Authorized Generics · **52** Pending ANDAs (24 Para IV) ## B. India Formulation Mix * **Secondary Sales Outperformance:** Despite modest reported growth due to brand rationalization and diabetes headwinds, secondary sales significantly outpaced the Indian Pharma Market (IPM) at **15.1%**. * **Growth Convergence:** Management expects reported and secondary sales growth to align by **Q3**, targeting a long-term **10% to 15% CAGR** through a shift toward higher-margin products. * **Therapy Leadership:** Maintained dominant positioning in core segments, ranking **2nd in Dermatology** and **3rd in Respiratory**, supported by 10 brands now featured in the IPM Top 300. * **Diabetes Recovery:** Performance is expected to rebound in **Q2** following the full supply restoration of **LIRAFIT** and recent SGLT2 inhibitor launches. ## C. North America Portfolio * **Sequential Momentum:** Robust quarter-on-quarter growth was fueled by injectable market share gains and three new Q1 launches, including generic **Adderall**. * **Pipeline Strategy:** Future growth is anchored in a "two-pronged" approach focusing on **respiratory and injectables**, utilizing both internal filings from the **Monroe facility** and strategic in-licensing. * **H2 Catalysts:** Growth is projected to accelerate in the second half via the launch of **generic Flovent (44 mcg)** and three additional partnered injectable products. ## D. Global Respiratory Brands * **RYALTRIS Expansion:** The flagship global brand is now commercialized in over **45 markets**, with launches planned for **10 to 12 additional countries** in the near term. * **Segment Resilience:** Branded respiratory products maintained strong month-on-month momentum, bolstered by recent approvals for two new respiratory assets. ## E. Oncology & Biosimilars * **Strategic Partnerships:** New collaborations for **TEVIMBRA** and **BRUKINSA** are expected to provide meaningful contributions to the India business over the next **2 to 3 years**. * **GLP-1 Leadership:** Achieved a dominant **50%+ market share** for **LIRAFIT** (Liraglutide biosimilar), establishing a foundation for further expansion into the GLP-1 agonist category. --- # 3. Geography & Market Mix ## A. Key Figures * **Europe Revenue:** **₹667.8 Cr** Q1 FY26 (-4% YoY) * **Emerging Markets Revenue:** **₹572.1 Cr** Q1 FY26 (+0.2% YoY) * **Russia Secondary Sales:** **21%** Q1 growth ## B. Europe Business Recovery * **Growth Inflection:** Management anticipates a pivot from the recent marginal decline to sustained double-digit growth starting in Q2 FY26. * **Strategic Product Launch:** The introduction of **WINLEVI** in the U.K. marks a key dermatology expansion, with a broader European rollout planned through the end of the fiscal year. ## C. Emerging Markets & LatAm Growth * **Regional Divergence:** Flat top-line performance masked robust **9% growth** in non-LatAm regions, supported by strong secondary sales in the Middle East and Africa. * **Respiratory Leadership:** **RYALTRIS** continues to gain market share as a leading nasal spray, with upcoming approvals in **Brazil and China** expected to catalyze full-year constant currency growth. * **Market Positioning:** Maintained high-tier rankings across key territories, including a **top 10** position in Brazil’s chronic respiratory segment and **3rd** in Kenya’s overall market. ## D. Russia & LatAm Trends * **Russian Outperformance:** Significant momentum in the region driven by the dermatology and respiratory portfolios, where the company ranks **9th** and **2nd** in respective market segments. * **LatAm Seasonality:** Quarterly softness attributed to low seasonal demand; however, the recent Mexico launch and pending Brazilian approvals for the respiratory pipeline provide a positive outlook. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **R&D Expenditure:** **7%** of revenue for the quarter (Guidance: **7.5%**) * **ISB 2001 Efficacy:** **79%** Overall Response Rate · **30%** Complete Response Rate * **Launch Cadence:** ~**10** products per year (Internal + Partnered) ## B. Innovation Platform Updates * **Platform Validation:** The **ISB 2001** deal validates the proprietary multispecific technology, positioning the firm as a key oncology innovator in emerging markets. * **Asset Monetization:** Management is currently overseeing two out-licensed autoimmune assets in clinical development, with roughly half of total R&D spend allocated to the **Ichnos Glenmark Innovation (IGI)** unit. ## C. Clinical Trial Milestones * **Oncology Expansion:** Initiated a global Phase III study for **QIN HAYO** in lung cancer (NSCLC), marking a significant move into neo-adjuvant and adjuvant treatments. * **Strategic Partnership Timeline:** Clinical costs for the ISB 2001 dose expansion are being fully absorbed internally until the **AbbVie** deal closes in **September 2025**. ## D. ANDA Filing & Commercialization Cadence * **Respiratory Outlook:** Anticipating a shift in the generic portfolio with respiratory ANDA approvals expected to commence in **H2 FY26**. * **Global Market Entry:** **QIN HAYO (Envafolimab)** has been filed across **15 markets**, with the first commercial launch slated for next fiscal year and early access already secured in **Kenya**. --- # 5. Manufacturing & Strategic Initiatives ## A. Key Figures * **AbbVie Upfront Allocation:** **$210M - $225M** reserved for IGI expenditures over three years ## B. Branded Model Transition * **Portfolio Optimization:** Transitioning toward a branded model by prioritizing high-margin, high-value assets while phasing out low-margin tail-end brands to bolster the overall margin profile. * **Consumer Business Restructuring:** Indian consumer operations transferred to a dedicated subsidiary to sharpen strategic focus; management confirmed no immediate plans for a capital raise in this entity. ## C. Partnership & M&A * **RYALTRIS Global Expansion:** Sustained growth driven by Menarini (EU) and Yuhan (South Korea), with a critical regulatory milestone expected in **Mainland China in FY '26** via Grand Pharma. * **Landmark AbbVie Collaboration:** Secured exclusive rights for AbbVie to commercialize **ISB 2001** in major global markets (North America, Europe, Japan, China), while retaining rights for emerging markets. * **Strategic Funding & Accounting:** The IFC deal is slated for closure by **September 2025**; the AbbVie upfront payment will be partially deferred to stabilize the P&L against future R&D spend, with the residual booked in **Q2**. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Monroe Facility Observations:** **5** FDA observations pending resolution * Antitrust Settlement: $37.75 million settlement with Direct Purchaser Plaintiffs ## B. Monroe Facility Status * **Path to Remediation:** Management has completed internal corrective actions and submitted responses to the FDA, aiming to restart commercial manufacturing within the current fiscal year. * **Operational Continuity:** The site continues to produce **exhibit batches** for key products, including **iron sucrose**, while awaiting regulatory clearance for accelerated filings. * **Resolution Outlook:** High management confidence in resolving the outstanding observations to unlock site capacity for commercial supply. ## C. Antitrust Litigation Settlements * **Legal De-risking:** Glenmark USA has settled multi-district price-fixing lawsuits with the direct purchaser class; notably, the company maintains a denial of all allegations and liability. * **Residual Legal Exposure:** While the DPP settlement is finalized, litigation remains ongoing with other plaintiff classes with no definitive timeline for total resolution. ## D. Tail-end Brand Rationalization * **India Business Realignment:** Strategic discontinuation of low-margin tail-end brands has caused temporary data divergence; secondary sales are expected to align with industry benchmarks (IQVIA/AWACS) by **Q3**. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin Target:** **23%+** stabilized outlook from Q3 onwards * **Net Working Capital Cycle:** **110 to 115 days** long-term sustainable target ## B. Margin & Revenue Trajectory * **Normalized Profitability:** Management anticipates a stabilized margin profile starting in the third quarter, following a non-comparable Q2 impacted by the **IGI deal flow**. * **Growth Sustainability:** Current performance levels are viewed as repeatable, underpinned by strategic initiatives and a robust product launch pipeline. ## C. Operational Efficiency * **Working Capital Optimization:** Achieving the targeted day-count in the cash cycle is identified as a critical lever to maintain the projected long-term margin trajectory.